Closing Remarks on the MM Treatment Landscape
Nora Biran, MD, and David Siegel, MD, offer closing remarks on the MM treatment landscape.
Future Directions in Multiple Myeloma Treatment
Myeloma experts share their thoughts on the future of multiple myeloma treatment.
Treatment Sequencing in MM
Experts on multiple myeloma compare their treatment sequencing strategies.
Bispecific Antibodies Under Investigation in Multiple Myeloma
Noa Biran, MD, offers insights on ongoing research with bispecific antibodies in multiple myeloma.
MM Therapies: Bispecific Antibodies and T-Cell Engagers
A comprehensive discussion on bispecific antibodies and T-cell engagers in the treatment of multiple myeloma.
Allogeneic CAR T-Cell Therapy and Other Technology Advances in Multiple Myeloma
Myeloma experts give an overview of allogeneic CAR T-cell therapy and other technology advances in MM.
The Impact of CAR T-Cell Therapy on MM Treatment Paradigms
Noa Biran, MD, and David Siegel, MD, discuss how CAR T-cell availability has impacted the field of multiple myeloma.
BCMA-Targeted CAR T-Cell Therapies in Multiple Myeloma
Experts on multiple myeloma discuss available BCMA-targeted CAR T-cell therapies and the KarMMa and CARTITUDE-1 clinical trials.
Evolving Treatment Paradigms in Multiple Myeloma
Noa Biran, MD, and David Siegel, MD, review the shifting treatment paradigms in multiple myeloma (MM).
Current Treatment Options for Patients With Multiple Myeloma
In this interview we discuss the standard of care and current treatment options for patients with multiple myeloma.
Emerging Therapies in the Treatment of Multiple Myeloma
In this interview we discuss the latest therapy developments in the treatment of multiple myeloma.
Managing Adverse Events of Multiple Myeloma and Anti–Multiple Myeloma Treatment: A Perspective on Carfilzomib
This series of articles provides clinicians with a resource for the use of carfilzomib in the management of patients with multiple myeloma.
2 Commerce Drive Cranbury, NJ 08512